

Health Assessment Questionnaire disability progression in early rheumatoid arthritis: Systematic review and analysis of two inception cohorts



Sam Norton, MSc, PhD^{1,a}, Bo Fu, MSc, PhD^{1,b}, David L. Scott, BSc, MD, FRCP^c, Chris Deighton, MD^d, Deborah P.M. Symmons, MD, FFPH, FRCP^{e,f}, Allan J. Wailoo, MSc, PhD^g, Jonathan Tosh, MSc, PhD^g, Mark Lunt, MSc, PhD^e, Rebecca Davies, MSc^e, Adam Young, MD, FRCP^h, Suzanne M.M Verstappen, MSc, PhD^{e,*}

^a Psychology Department, Institute of Psychiatry, King's College London, London, UK

^b Centre for Biostatistics, Institute of Population Health, The University of Manchester, Manchester, UK

^c Department of Rheumatology, Kings College Hospital, London, UK

^d Department of Rheumatology, Medical Specialities Out-Patients, Rehabilitation Block, Royal Derby Hospital, Derby, UK

^e Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester Academic Health Science Centre, Stopford Building, Oxford Rd, Manchester M13 9PT, UK

^f NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, Manchester, UK

^g School of Health and Related Research, University of Sheffield, UK

^h Early Rheumatoid Arthritis Study, City Hospital, St Albans, UK

ARTICLE INFO

Keywords:

Systematic review
Latent class growth model
Health Assessment Questionnaire
Rheumatoid arthritis
Inflammatory polyarthritis
Predictors

ABSTRACT

Objective: The Health Assessment Questionnaire is widely used for patients with inflammatory polyarthritis (IP) and its subset, rheumatoid arthritis (RA). In this study, we evaluated the progression of HAQ scores in RA (i) by systematically reviewing the published literature on the methods used to assess changes in functional disability over time and (ii) to study in detail HAQ progression in two large prospective observational studies from the UK.

Methods: Data from two large inception cohorts, ERAS and NOAR, were studied to determine trajectories of HAQ progression over time by applying latent class growth models (LCGMs) to each dataset separately. Age, sex, baseline DAS28, symptom duration, rheumatoid factor, fulfilment of the 1987 ACR criteria and socio-economic status (SES) were included as potential predictors of HAQ trajectory subgroup membership.

Results: The literature search identified 49 studies showing that HAQ progression has mainly been based on average changes in the total study population. In the HAQ progression study, a LCGM with four HAQ trajectory subgroups was selected as providing the best fit in both cohorts. In both the cohorts, older age, female sex, longer symptom duration, fulfilment of the 1987 ACR criteria, higher DAS28 and lower SES were associated with increased likelihood of membership of subgroups with worse HAQ progression.

Conclusion: Four distinct HAQ trajectory subgroups were derived from the ERAS and NOAR cohorts. The fact that the subgroups identified were nearly identical supports their validity. Identifying distinct groups of patients who are at risk of poor functional outcome may help to target therapy to those who are most likely to benefit.

© 2014 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-NC-SA license (<http://creativecommons.org/licenses/by-nc-sa/3.0/>).

ERAS received grants from Arthritis Research UK, UK the British United Providence Association (BUPA) Foundation, UK and the NIHR, UK through E&H CLRN. NOAR is funded by Arthritis Research UK, UK (Grant no. 17552).

* Corresponding author.

E-mail address: Suzanne.Verstappen@manchester.ac.uk (S.M. Verstappen).

¹Shared first author.

Introduction

The Health Assessment Questionnaire (HAQ) is the most widely used measure of function in studies of inflammatory polyarthritis (IP) and its subset, rheumatoid arthritis (RA) [1,2]. Worse functional disability is associated with increased cardiovascular and all-cause mortality [3,4], joint damage [5] and work disability in patients with IP and RA [6,7]. Functional disability is mainly

<http://dx.doi.org/10.1016/j.semarthrit.2014.05.003>

0049-0172/© 2014 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-NC-SA license (<http://creativecommons.org/licenses/by-nc-sa/3.0/>).

associated with disease activity in early RA and with radiographic joint damage in patients with established disease. It is therefore often used as an outcome measure to assess the impact of disease over time [8–10]. Predictors of worse functional disability in the long-term include baseline or 1-year HAQ score [11–13], older age [12,14], female gender [12,14], disease activity [11,13–15], rheumatoid factor (RF) positivity or anti-citrullinated protein antibody (ACPA) positivity [16], radiographic damage [5,13,17,18], number of co-morbidities [10,19,20], low education [15] and low socio-economic status (SES) [17,21,22].

Previous research has suggested that the mean HAQ score over time is J-shaped with an initial improvement after treatment commencement followed by an insidious decline in patients with early RA [11,15,23]. However, the focus of most of these studies was on the average change over time in the total study population calculating mean changes in HAQ score over time or applying simple linear regression models to determine the association between disease duration and HAQ progression. In the last two decades, more advanced methods have become available to measure longitudinal data, such as repeated measurement regression analysis. However, in most studies, the change in HAQ scores over time has been measured at the group level. Few studies have attempted to identify subgroups defined in terms of their HAQ trajectory in IP and RA patients or considered their validity across cohorts. In a recent study that included patients with early RA recruited to the Early Rheumatoid Arthritis Study (ERAS) and followed up for 10 years, latent growth mixture modelling (LGMM) was used to determine whether the study population comprises distinct subgroups of patients with differing trajectories of functional disability [24]. It is important to determine if similar results can be found in other RA populations as well. In general, identification of distinct groups of patients who are at risk of poor outcome may help to target therapy to those who are most likely to benefit in the clinic.

The objectives of this study were (i) to give an overview of the methods used in the literature to assess functional disability over time and (ii) to identify common trajectories of HAQ progression over 15 years in two large prospective observational studies from the UK, i.e., ERAS and the Norfolk Arthritis Register (NOAR).

Methods

Systematic literature review

MEDLINE was searched to identify articles describing changes in HAQ scores over time in patients with RA or undifferentiated polyarthritis. The following keywords were used: (([exp Arthritis, Rheumatoid/] OR [inflammatory polyarthritis.mp] OR [undifferentiated arthritis.mp]) AND ([health assessment questionnaire\$.mp] OR [HAQ.mp] OR [functional.mp AND disability.mp])) NOT ([exp Arthritis, Juvenile Rheumatoid/] OR [JIA.mp]) NOT ([clinical trial, phase i/ OR clinical trial, phase ii/ OR clinical trial, phase iii/ OR clinical trial, phase iv/ OR controlled clinical trial/ OR randomized controlled trial/] OR [exp case reports/] OR [randomized clinical trial.mp]). The search was limited to the years “1980–2012” and English language. Studies were selected if they met the following inclusion criteria: Follow-up duration/disease duration ≥ 3 years, multiple (i.e., ≥ 3) cross-sectional assessments of HAQ in case of cross-sectional analysis, (M)HAQ used to measure functional disability and no intervention study (Fig. 1 for selection procedure). References of identified reviews and selected studies were checked for eligible articles.

HAQ trajectory study: Patients recruited to the Early Rheumatoid Arthritis Study (ERAS) and the Norfolk Arthritis Register (NOAR)

ERAS is an inception cohort to which consecutive patients thought to have RA by a consultant rheumatologist were recruited




Fig. 1. Selection process publications.

from the outpatient clinics of nine rheumatology departments in the UK between 1986 and 1997. Patients were included if they had a symptom duration of less than 2 years and were disease-modifying anti-rheumatic drug (DMARD) naive [12,25]. Patients in ERAS were subsequently excluded if the diagnosis changed, for example, apparent early RA evolving to classical lupus or osteoarthritis.

NOAR is a primary care-based inception cohort of patients with early IP recruited in Norfolk, UK. Consecutive patients aged over 16 years with swelling in ≥ 2 joints that lasted ≥ 4 weeks were referred via the GP or rheumatologist to NOAR between 1990 and 1994 [26,27]. This analysis included all patients who had not been given a consultant diagnosis other than RA, undifferentiated IP, psoriatic arthritis or post-viral arthritis to explain their symptoms. Patients whose disease has gone into spontaneous long-term remission (no inflamed joints at the 3rd or 5th anniversary and not on disease-modifying anti-rheumatic drugs (DMARDs) or steroids) were followed up beyond the 5th anniversary; otherwise patients were followed up until the 5th anniversary if applicable.

Clinical and laboratory assessments and socio-economic status

Standard clinical assessments were made by trained research nurses in both studies at baseline and included date of symptom onset and number of swollen and tender joints. RA was defined according to the 1987 ACR criteria and applied cumulatively. At each visit, DMARD and biologics use, including start and stop date, was recorded. The two cohorts differed in laboratory assessments. In ERAS, routine haematology tests included the erythrocyte sedimentation rate (ESR) measured according to Westergren test and routine serology including RF. In NOAR, blood was collected and stored in -80°C freezers to measure RF (positive > 40 mg/L) and C-reactive protein (CRP). Due to these small differences in data collection and visual analogue scale general well-being missing in NOAR, the 4-component DAS28 score based on ESR values was calculated in ERAS and the three-component DAS28 score based on CRP was calculated in NOAR.

Socio-economic status was defined as an area-level categorical variable, based on the Index of Multiple Deprivation (IMD) 2007. In the IMD, the UK is divided into “super output areas,” with a minimum population of 1000 (mean 1500). Information on income, employment, health, education, barriers to services, crime and living environment is used to assign a deprivation score to each super output area. These scores are then ranked across the country. For this study, we used postal codes to assign each patient

to a nationwide deprivation rank and then to a nationally determined quartile of deprivation.

All patients completed the disability index of the modified British version of the Stanford Health Assessment Questionnaire (HAQ) [28] at baseline and at subsequent follow-up visits. The HAQ comprises 20 questions in eight categories. A score of 0 (no difficulty), 1 (some difficulty), 2 (much difficulty or need of assistance) or 3 (unable to perform) is given to each question; the highest score in each category represents the score for that category. The sum of scores is then divided by the number of categories, yielding a total score ranging from 0 (best) to 3 (worst). Although patients in ERAS completed the HAQ questionnaire annually after inclusion in the cohort, to resemble the NOAR assessment visits and to ensure that the models were validated using as similar datasets as possible, HAQ scores obtained at 1, 2, 3, 5, 7, 10 and 15 years after inclusion were used for these analyses. Sensitivity analysis using all the ERAS HAQ follow-up data indicated that this did not affect either the number or the shape of the trajectories in the best-fitting model. Patients with missing HAQ data at baseline and a symptom duration > 2 years were excluded from the analysis.

All patients gave written informed consent and both studies were approved by the relevant UK National Health Service Research Ethics Committees.

Statistical analysis

Baseline clinical and demographic data are described for both the cohorts. To determine trajectories of HAQ progression over time, latent class growth models (LCGMs) [29] were applied to the ERAS and NOAR datasets separately and independently. The model captures common characteristics of HAQ trajectories within a subpopulation through latent classes. A mixture of censored normal distributions was used to model the longitudinal HAQ outcomes over time. A censored normal LCGM was chosen because HAQ is a bounded score at 0 and 3. To determine the number of trajectory subgroups, we considered several factors including model-fit statistics such as the Akaike Information Criterion (AIC), the Bayesian Information Criterion (BIC) and the Lo–Mendell–Rubin likelihood ratio test. The best-fitting model was then identified, leaning towards parsimony in the number of trajectory groups. The model is based on a joint likelihood including two parts: an outcome model and a logistic regression model for class membership. Several time-dependent covariates, such as linear, quadratic, cubic and reciprocal (in ERAS) terms of year since registration, were included in the outcome part to model the trajectory shape within subgroups. Age, gender, baseline DAS28, symptom duration, RF, fulfilment of the ACR criteria for RA and SES were included as predictors of class membership. Odds ratios (ORs) and 95% confidence intervals (95% CI) were calculated for each class membership group with the lowest class membership as reference. Each patient was assigned to one of the trajectory groups for which he/she had the highest probability of membership. We also describe the percentage of patients receiving methotrexate and the percentage of patients using biologics during follow-up within each subgroup membership group. The LCGM analyses were performed by using M-Plus or SAS macro PROC TRAJ.

Results of systematic literature review

Description of identified studies

A total of 49 studies were identified: 17 studies including patients with early RA or IP (mean/median disease duration

< 2 years or including a group of patients with disease duration < 2 years) [8,10,13–15,30–41] and 32 studies including patients with a disease duration of more than 2 years [19,20,42–71] (Table 1). The follow-up duration varied between studies ranging from a minimum of 3 years (i.e., inclusion criteria) [38,41,42,55,58,66] to > 15 years [31,33,51,57,67]. Age and gender distribution were representative of a general RA population, except in one study in which only women were included [10].

Methods used to evaluate change in HAQ score over time

Overall, different methods were used to assess change in HAQ score over time in both the early RA group and the established RA group (Table 1, column 8). In 29 studies, HAQ scores were measured cross-sectionally at more than 3 time-points following the same study population over time or for more than 3 groups of patients with increasing disease duration [10,13–15,30–32,34–39,41,42,45–47,51,53–55,58,59,62,64,66,68,69]. A J-shaped trajectory was observed in 12/14 (86%) cross-sectional studies including patients with early disease [10,13–15,30,32,34–39,41] and in 4/9 (44%) studies including patients with established disease [42,58,62,64].

Annual HAQ progression rates are shown in the last column of Table 1. In eight of the 29 cross-sectional studies, change in HAQ score was calculated by the following methods: subtracting HAQ scores obtained at two different time-points divided by the number of years of follow-up, calculating the median difference from ≤ 3 years disease duration groups [51], calculating median change during 3-year intervals [10], calculating mean change from the first assessment [34,37], calculating median change from 0 to 6 months and 2 until 3 years [66], calculating annualised AUC [55], calculating the mean effect size [46] or estimating the annual change in those with early RA and those with established RA [43].

In other studies, linear regression analysis was used to assess the association between disease duration and (change in) HAQ score including one time point per patient [10,15,19,31,33,44,48,61,64,65,68,71], including multiple time-points per patient [49,50,52,70], calculating the annual percentage reduction in average disability [56], including all of the available study observations measured during follow-up by using a dynamic panel data model for repeated measurements applying pooled time-series regression analysis, generalised estimating equations (GEE) [20,33,60,63,69,72], linear mixed-effects models with a random effect for the repeated observations [8,67,71], marginal structural model [40] and generalised linear models [47,60].

In a few studies, different regression models were constructed and the best fit was tested. In one study by Leigh et al. [50], methods used in economics (Tobit, Fixed effects and dummy variable for cohort models) were applied to address the problems of censoring, panel data and cohort effects. In another study by Leigh and Fries [73], six different multiple regression analyses were performed, including individual or combinations of covariates (eg, years of disease duration, years of disease duration², gender, education and age). Wolfe [33] constructed various group and individual linear and non-linear (fractional polynomial) regression models. Three main findings were observed when analysing at a group level: (i) HAQ disability scores were already high at disease onset; (ii) annual HAQ progression was very slow (i.e., ~ 0.03 units per year) and (iii) the explained variance was only 5%. However, when including covariates to the model, the fit of the model became better and 51% of the variance could be explained. When applying a fractional polynomial model (eg, including HAQ score and HAQ score^{fraction} in the model), the explained variance was 37%.

Overall, change in HAQ scores was mainly based on analysis in the total study population without identification of distinct

Table 1
Baseline demographic and clinical characteristics of previous publications

Study (country)	n	Age	Female gender	Disease duration	Follow-up duration	HAQ baseline	Analysis method	Progression HAQ score	HAQ scores/change over time score
van Zeben et al. [30] (NL)	127	DR4−: 34.6 (9.0) DR4+: 37.7 (8.0)	NA	1.7 (1.5) yrs 1.6 (1.4) yrs	6.7 (2.2) 6.5 (1.6)	0.6 (0.60) 0.70 (0.56)	Cross-sectional	Mean (SD) score at 1, 4 and 8 yrs	DR4−: 0.69 (0.6); 0.50 (0.62); 0.67 (0.73). DR4+: 0.70 (0.56); 0.88 (0.68); 1.05 (1.02)
Wolfe et al. [31], (USA)	561	53.7 (14.4) 55.0 (14.4) 55.4 (11.4) 54.9 (11.9) 62.5 (8.6)	72.0 % 72.7 % 82.1 % 63.2 % 80.0 %	1.6 (0.56) yrs 6.0 (1.52) yrs 11.2 (1.54) yrs 16.2 (1.53) yrs 21.3 (1.56) yrs	NA	NA	Cross-sectional, least square methodology using all time-points for each patient (Figure only)	Mean (SD) score at first visit: 0–2; 2–7; 7–12; 12–17 and 17–22 yrs	0.82 (0.63); 0.90 (0.61); 1.03 (0.58) 1.11 (0.63); 1.19 (0.76)
Guillemin et al. [15] (NL and FR), EURIDISS	NL = 221 FR = 116	54.8 53.9	1.9 (M/F) 2.3 (M/F)	< 1 yrs 1–2 yrs 2–3 yrs 3–4 yrs 4–5 yrs	5 yrs	1.18 1.05	Cross-sectional crude mean values and mean-adjusted values. Multivariate linear regression.	Mean score and per yr increase disease duration (I) and disease duration, disease duration ² (II)	< 1 yrs: 0.99 and 1.04 1–2 yrs: 0.83 and 0.94 2–3 yrs: 1.22 and 1.16 3–4 yrs: 1.29 and 1.23 4–5 yrs: 1.55 and 1.43 I: $\beta = 0.10$; II: $\beta = -0.13$ and $\beta = 0.022$
Munro et al. [32] (UK)		I = 53 (44–60) II = 54 (44–64) III = 57 [50–65]	I = 75% II = 85% III = 79%	I = 0–2 yrs II = > 2–5 yrs III = > 5 yrs	5 yrs	I = 1.88 (1.32–2.38) II = 1.75 (1.19–2.25) III = 2.00 (1.38–2.38)	Cross-sectional	Median (IQR) score at baseline and at 1, 2, 3, 4 and 5 yrs	Group I: 1.06 (0.53–1.88); 1.00 (0.13–1.38); 1.00 (0.44–1.75); 1.13 (0.63–2.00); 1.25 (0.50–2.00), group II: 1.13 (0.66–1.72); 1.25 (0.75–1.83); 1.27 (0.75–1.88); 1.57 (0.88–2.25); 1.81 (1.03–2.22), group III, 1.57 (0.97–2.22); 1.50 (1.00–2.25); 1.75 (1.13–2.38); 1.75 (0.88–2.35); 2.13 (1.23–2.50)
Drossaers-Bakker et al. [10] (NL)	112	37 (8.4)	100%	1.0 (0–5) yrs	Median = 12 (range: 10–14) yrs	0.75	Cross-sectional and multiple linear regression at 12 yrs	Median change: 0–3; 3–6 and 6–12 yrs	0 (−1.89, 1); 3–6 yrs = 0 (−1.25, 1.29); 6–12 yrs = 1.3 (−1.0, 2.16) $\beta = 0.043$ (95% CI: −0.01 to 0.097)
Wiles et al. [14] (UK)	684	55 (42–68)	67%	5.9 (2.9–11.9) months	5 yrs	0.81 (0.25–1.50)	Cross-sectional at different time-points	Median (IQR) score at baseline and at 1, 2, 3 and 5 yrs	0.81 (0.25–1.50); 0.50 (0.125–1.375); 0.625 (0.125–1.375); 0.625 (0.25–1.375), 0.875 (0.25–1.625)
Wolfe [33] (US)	1843	54.6 (12.7) (S)	72% (S)	0.9 (0.5) (S) yrs	16.7 (1.09) yrs	1.08 (0.69)	1) Ordinary least-squares linear regression using one data point in time per patient 2) GEE (all) 3) GEE (S)	Annual change	1) 0.020 (95% CI 0.016–0.24) 2) 0.030 (95% CI 0.027–0.034) 3) (S) 0.020 (95% CI 0.01–0.03)
Kroot et al. [34] (NL)	S: 50 622	53.3 (18–86)	62%	< 1 yr	10 yrs	0.67 (0–1.97)	Cross-sectional	Annual mean scores from baseline until 10 yrs (mean difference from baseline)	Baseline = 0.67; 0.49 (−0.25); 0.55 (−0.23); 0.53 (−0.24); 0.56 (−0.18); 0.55 (−0.19); 0.56 (−0.10); 0.63 (−0.01); 0.65 (−0.01); 0.65 (−0.07)

Welsing et al. [8], (NL)	378	54.8 (14.8)	63.8%	< 1 yr	6.29 (3.8) yrs	0.47 (0.17–1.1)	Adjusted linear mixed model	Adjusted annual change	$\beta = \sim 0.02$ units per yr
Ahlmén et al. [35] (SE)	W: 343 M: 206	W: 54 (16) M: 61 (13)	62%	< 1 yr	5 yrs	W: 1.05 (0.62) M: 0.84 (0.55)	Cross-sectional at different time-points	Mean (SD) score at baseline and at 1, 2 and 5 yrs	W: 1.05 (0.62); 0.62 (0.58); 0.65 (0.65); 0.73 (0.68) M: 0.84 (0.55); 0.44 (0.49); 0.47 (0.52); 0.51 (0.56)
Combe et al. [13] (FR)	191	50.5 (14.7)	73%	3.6 (2.6) months	5 yrs	1.3 (0–2.75)	Cross-sectional at different time-points	Mean (range) score at baseline and at 3 yrs and 5 yrs	1.3 (0–2.75); 0.5 (0–2.5); 0.6 (0–3.0)
Benton et al. [36] (NZ)	34	Median = 48.5	62%	Median = 4 months	6 yrs	0.33 (0–1.6)	Cross-sectional at different time-points	Median score at baseline and at 1 and 6 yrs	0.6; 0.16; 0.33
Persson et al. [37] (SE)	158	52 (42–59)	64%	10 (6–14) months	4 yrs	0.92 (0.60)	Cross-sectional at different time-points	Mean (SD) score (mean (SD) change from yr 1) at 1, 2, 3, 4 and 5 yrs	0.918 (0.60); 0.843 (0.56) [–0.062 (0.43)]; 1.009 (0.60) [0.085 (0.50)]; 0.957 (0.61) [0.049 (0.49)]; 0.989 (0.57) [0.085 (0.53)]
Proudman et al. [38] (AU)	61	56 (14)	76%	12 (6–104) weeks	36 months	0.9 (0.5)	Cross-sectional at different time-points	Mean (SD) score at baseline and at 12, 24 and 36 months	0.9 (0.5); 0.3 (0.4); 0.2 (0.3); 0.3 (0.4)
Courvoisier et al. [39] (FR)	112	50.4 (12.6)	80.3%	3.9 (2.8) months	10 yrs	1.29 (0.71)	Cross-sectional at different time-points	Mean (SD) score at baseline and at 3, 5 and 10 yrs	1.29 (0.71); 0.53 (0.62); 0.57 (0.62); and 0.75 (0.71)
Farragher et al. [40] (UK)	1084	53 (41–66)	65.4%	4 (2–10) months	10 yrs	0.75 (0.25–1.375)	Change and marginal structural model	Change over 10 yrs and annual rate, adjusted MDIC treated vs not treated (T vs NT)	T: 0.24 (95% CI: 0.14–0.33) and NT: 0.13 (95% CI: 0.05–0.21) Adj MDIC: –0.01 (95% CI: –0.20 to 0.19)
Benka et al. [41] (SK)	116	47.6 (12.4)	85%	22.1 (16.1) months	3 yrs	1.15 (0.68)	Cross-sectional at different time-points	Mean (SD) score at baseline and at 1, 2 and 3 yrs	1.15 (0.68); 1.08 (0.66); 1.05 (0.72); 0.98 (0.74)
<i>Disease duration > 2 yrs</i>									
Fries et al. [42] (US)	322	~51 yrs	NA	~12 yrs	36 months	0.80	Cross-sectional at different time-points	Mean scores at baseline and at 6, 12, 18, 24, 30 and 36 months	0.80; 0.78; 0.83; 0.83; 0.93; 1.11; 1.18
Sherrer et al. [43] (US)	681	62 (13)	72%	10 (6) yrs	12 (6) yrs	Cross-sectional: not available	Mean HAQ score at the end of the study	Annual rate in first few yrs and after 15 yrs	0.10 and 0.02
Wolfe and Cathay [44]	1274	10.3 (12)	71%	7.4 (9.11) yrs	Mean = 3.9 (3.31)	0.98 (0.76)	Linear regression at baseline and for change in HAQ after baseline	HAQ score and change in HAQ	Baseline: $\beta = 0.013$ HAQ score per yr increase in disease duration and $\beta = 0.11$ change HAQ score per increase in disease duration
Epstein et al. [45] (US)	574	55	75%	10.2 yrs	5 yrs	1.18	Cross-sectional at different time-points non-gold vs gold group: GEE	Unadj and adj mean score at baseline and at 1, 2, 3, 4 and 5 yrs. GEE only <i>p</i> -value shown	Unadj: 1.30 vs 1.09; 1.24 vs 1.08; 1.30 vs 1.16; 1.32 vs 1.16; 1.41 vs 1.21; 1.14 vs 1.00; Adj: 1.18 vs 1.20; 1.24 vs 1.27; 1.25 vs 1.29; 1.35 vs 1.32; 1.08 vs 1.11

Table 1 (continued)

Study (country)	n	Age	Female gender	Disease duration	Follow-up duration	HAQ baseline	Analysis method	Progression HAQ score	HAQ scores/change over time score
Hawley and Wolfe [46]	157	50.8 (12.5)	75%	6.7 (8.2) yrs	Mean = 9.8 SD 0.75)	0.5 (0.5)	Cross-sectional at different time-points	Mean (effect size from baseline) at baseline and at 2, 5 and 10 yrs	0.5 (NA); 0.5 (–0.01); 1.3 (–1.63); 1.6 (–2.39)
Leigh et al. [47] (US)	L: 209 D: 54	L: 52 (14) D: 66 (10)	L: 86% D: 63%	L: 12 (9) yrs D: 18 (9) yrs	8 yrs	L: 1.09 (0.83) D: 1.75 (0.88)	Cross tabulation (L) at follow-up and all (A) patients including deceased Multiple regression pooling data including all time-points. Different models (duration, duration ² and duration ³)	Annual rate	L cohort: 0.018 per yr L (0–10 yrs) W vs M: 0.017 vs –0.003 L (10–20 yrs) W and M: 0.016 vs –0.010 A (0–10 yrs) W and M: 0.032 vs 0.063. A (10–20 yrs) W and M: 0.029 vs 0.079; Linear model: $\beta = 0.0518$
Guillemin et al. [48] (FR)	82	53.3 (17.8–89.9)	69.5%	7.2 (0–31) yrs	7.2 (0–31) yrs and < 5 yrs (mean 2.3) vs 5 yrs (mean 14.7)	1.5 (0–3)	Multiple regression total sample and for < 5 yrs and > 5 yrs disease duration groups	Annual adjusted: additive model and multiplicative model	Total: $\beta = 0.003$ ($p < 0.05$) and $\beta = 0.002$ ($p < 0.05$); < 5 yrs $\beta = 0.007$ (NS) and 0.007 (NS) and > 5 yrs, $\beta = 0.003$ ($p < 0.05$) and $\beta = 0.003$ ($p < 0.05$)
Ward and Leigh [49] (US)	188 94	Married (MA): 54.6 (11.7) Unmarried (UNM): 54.0 (13.4)	78% 94%	13.5 (9.0) yrs 15.0 (9.2) yrs	~9.5 yrs	1.1 (0.8) 1.3 (0.9)	Pooled time-series regression analysis	Mean-adjusted annual rate (MA vs UNM); all patients; patients with complete follow-up; men and women	$\beta = 0.01$ vs $\beta = 0.03$; $\beta = 0.007$ vs $\beta = 0.02$; $\beta = 0.006$ vs $\beta = 0.03$; $\beta = 0.01$ vs $\beta = 0.03$
Gardiner et al. [19] (UK)	175	55.4 (range: 18–86)	82%	12.7 (range: 0–43) yrs	5 yrs	1.77 (0.75)	Multiple linear regression analysis using baseline HAQ and change over 5 yrs	Adjusted rate and mean annual change over 5 yrs	$\beta = 0.019$ (SE 0.01) and 0.03 units/yr
Leigh et al. [50] (US)	L: 209 D: 54 LFU: 67	L: 52 (14) D: 66 (1) LFU: 55 (12)	L: 86% D: 63% LFU: 85%	L: 12 (9) yrs D: 18 (9) LFU: 14 (9)	L: 8 yrs D: until last visit LFU: until last visit	L: 1.16 (0.81) D: 1.75 (0.88) LFU: 1.20 (0.90)	Using all valid observations during follow-up: 1) Linear regression 2) Tobit regression 3) OLS fixed effects by cohort (I = 0–9, II = 9–19 and II = > 19 yrs disease duration at baseline) 4) Cohort OLS fixed effects	Annual slope	1) $\beta = 0.014$ 2) $\beta = 0.014$ 3) $\beta = 0.019$ 4) I, $\beta = 0.003$; II, $\beta = 0.0001$; III, 0.017 5) I, $\beta = 0.0210$; II, $\beta = 0.0103$; III, $\beta = 0.0293$

Lassere et al. [51] (AU)	358	61. (12.7)	73.2 %	13.6 (10.4) yrs	≤ 3 yrs > 3 to ≤ 6 yrs > 6 to ≤ 12 yrs > 12 to ≤ 18 yrs > 18 yrs	Median (IQR) 0.250 (0.781) 0.625 (1.188) 0.875 (1.25) 1.125 (0.75) 1.375 (1.25)	Median difference Percentile curves using the weighted average method.	Median difference (95% CI) from 3 yrs: 3–6; 6–12; 12–18 and > 18 yrs NA	–0.25 (–0.500, 0.001); –0.375 (–0.625, –0.125); –0.625 (–0.875, –0.375); –0.875 (–1.125, –0.500) NA
Ward et al. [52] (US)	282	52.5 (11.7) ^a 52.6 (11.4) ^b	84% 77%	13.6 (9.1) yrs 14.0 (8.6) yrs	10.5 (3.8) yrs 10.0 (4.1) yrs	1.03 (0.8) 1.00 (0.8)	Pooled time-series regression analysis	Adjusted annual rate	$\beta = 0.015$ (95% CI: 0.012, 0.018) ^a $\beta = 0.019$ (95% CI: 0.014– 0.024) ^b
Clarke et al. [53] (CA)	130	62.4 (9.9)	83.1%	22.5 (10.5) yrs	> 5yrs	1.6 (0.7)	Cross-sectional for different disease duration groups	At mean disease duration: 3.8; 7.8; 12.5; 17.5, 22.2; 26.9; 36.6	1.3 (0.5); 1.2 (0.7); 1.3 (0.8); 1.4 (0.8); 1.5 (0.8); 1.5 (0.7); 1.8 (0.6)
Gordon et al. [54] ^c	289	59 (19–82)	73%	10 (1–61) yrs	10 yrs	13 (0–60)	Cross-sectional at different time- points	Median (range) score at baseline at 5 and 10 yrs	13 (0–60); 13 (0–60) and 23 (0–60) 0.33 (0.03)
Hurst et al. [55] (US)	924	54.9 yrs	72%	6.7 yrs	MTX: 3.23 (SE 0.13) HCQ: 2.61 (SE 0.17) Gold: 1.96 (SE 0.17)	1.60 (SE 0.03) 1.18 (SE 0.04) 1.52 (SE 0.05)	AUC = (area above baseline HAQ reference line) – (area below baseline reference line)	Mean (SE) annualised AUC averted	0.18 (0.03) 0.38 (0.04)
Krishnan and Fries [56] (US)	3035	55 (14.3)	76%	4.7 (4.5) yrs	5.3 (4.3) yrs	1.03 (0.74)	Generalised Least square regression Ordinary least square regression using average cumulative data	Unadjusted and adjusted annual percentage reduction	Unadj: 2.7% (2.3–3.1); Adj: 2.0% (1.8–2.2) Unadj: 2.8% change (2.4–3.2); Adj: 2.1 (1.7–2.5)
Krishnan et al. [57] (US and CA)	6436	58.5 (48.0–67.4)	74%	8.0 (2.3–16.7) yrs	20 yrs	1.13 (0.5–1.8)	Percentile curves	Smoothed growth curves, men and women separately per age group	See article
Demange et al. [58] (Europe)	542	52.5 (12.1)	69%	2.1 (1.3) yrs	3 yrs	0.99 (0.71)	Cross-sectional at different time- points	Mean (SD) score at baseline (= 1 yr), 2 yrs and 3 yrs	0.99 (0.71); 0.98 (0.74); 0.99 (0.75)
Baddoura et al. [59] (LB)	298	51.5 (14.7)	87.6%	8.9 (8.7) yrs	Cross-sectional in 5 disease duration groups	0.62 (0.65) M-HAQ	Cross-sectional for 5 disease duration groups	Disease duration: < 1 yr; ≥ 1 and < 2 yrs; ≥ 2 and < 5 yrs; ≥ 5 and < 10 yrs; ≥ 10 yrs	0.69 (0.64); 0.53 (0.50); 0.43 (0.45); 0.45 (0.50); 0.95 (0.80)
Sokka et al. [60] (FI)	RA: 863 C: 1176	55	70%	Mean 11.3 yrs (previous pub)	5 yrs	0.71 (0.71) 0.17 (0.41)	Generalised linear models	Annual rate	0.01 per yr 0.01 per yr
Shinozaki et al. [61] (JP)	1265	57.9 (12.3)	81.5%	11.2 (12.3) yrs	4 yrs	0.81 (0.75)	Linear regression. Slope regression line based on mean value at 6 monthly intervals	Per 6 months: MMP3+/RF+; MMP3+/RF–; MMP3–/RF+; MMP3–/RF–	$\beta = 0.0179$ (95% CI: 0.014– 0.022); $\beta = 0.016$ (95% CI 0.012–0.021); $\beta = 0.052$ (95% CI: –0.002–0.033); $\beta = 0.02$ (95% CI: 0.012–0.004)
Odegard et al. [62] (NO)	149	50.2 (12.5)	76%	2.2 (1.2) yrs	10 yrs	0.86 (0.61)	Cross-sectional at different time- points	Mean (SD) score at 1 yr, 2 yrs, 5 yrs and 10 yrs	0.86 (0.61); 0.85 (0.62); 0.85 (0.65); 0.86 (0.60); 0.91 (0.70)

Table 1 (continued)

Study (country)	n	Age	Female gender	Disease duration	Follow-up duration	HAQ baseline	Analysis method	Progression HAQ score	HAQ scores/change over time
Ikuni et al. [70] (JP)	CS: 55 NCS: 159	CS: 56.6 (11.2) NCS: 55.3 (11.4)	CS: 76.4% NCS: 74.2%	CS: 10.71 (11.17) yrs NCS: 7.62 (6.92) yrs	4 yrs	CS: 0.48 (0.61) NCS: 0.40 (0.49)	For each patient linear regression analysis for all available HAQ data of that individual	Mean annual rate	CS: $\beta = 0.0058$ NCS: $\beta = -0.0090$
Gonzalez-Alvaro et al. [63] (ES)	789	61 (13)	72%	~13 (13) yrs	4 yrs	1.2 (0.9)	Fitted population-averaged model by weighted estimating equations nested by patient and visit	Mean annual rate	2004 vs 2000: $\beta = -0.09$ (0.03 to 0.15) and adj $\beta = 0.15$ (0.07 to 0.22)
Ranganath et al. [64] (US)	889	56 (14.6) 56 (13.7) 60 (12.0)	77% 75% 77%	< 3yrs 3–5 yrs > 5 yrs	6–12 months	0.57 (0.5) 0.47 (0.4) 0.61 (0.5)	Cross-sectional in different disease duration groups Multivariate linear regression analysis	Mean (SD) and mean change (SD) in disease duration groups: < 3 yrs, 3–5 yrs and > 5 yrs Change in HAQ per 10 yrs increase disease duration	0.57 (0.5) and -0.13 (0.5); 0.47 (0.4) and -0.03 (0.4); 0.61 (0.5) and -0.07 (0.4) $\beta = 0.027$ (95% CI: 0.002–0.052)
Ikuni et al. [65] (JP) Bazzani et al. [66] (IT)	W: 4027 M: 797 1010	W: 57.8 (12.8) M: 60.0 (12.8) 55.7 (13.0)	83.5% 83%	W: 10 (5–16) yrs M: 8 (4–14) yrs 9.32 (7.3) yrs	One time point per patient 3 yrs	W: 0.63 (0.13–1.38) M: 0.25 (0–0.875) 1.46 (0.61)	Multiple linear regression Cross-sectional at different time-points	Adjusted annual rate Median change: baseline to 6 months and 2nd to 3rd year	W: 0.0194 M: 0.0067 Change: 0.34 and 0.64
Wolfe and Michaud [67]	18,485	59.9 (13.0)	76.7%	9.7 (4.4–18.1) yrs	Lifetime 10 yrs	NA 1.06 (0.73)	Annualised lifetime rates of progression Annualised observed rates of progression	Mean per yr	$\beta = 0.016$ (95% CI: 0.015–0.017) $\beta = 0.013$ (95% CI: 0.010–0.015)
Michaud et al. [20] (US)	18,485	~60	77%	~12 yrs	3.7 (3.2) yrs	1.06 (0.73)	GEE, adjusted for confounders	Overall adjusted annual rate Separate analysis for gender, age, education, smoking status, co-morbidity, year of RA onset, severity of disease and treatment allocation	0.014 (0.012–0.015) See article

Staples et al. [68] (AU)	1801	55.9 (12.6)	73.0%	13.0 (10.4) yrs	60 months	1.64 (0.66) (derived from EQ-5D)	Multiple linear regression at baseline and cross-sectional at follow-up	Adjusted annual rate Baseline and 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60 months	$\beta = 0.012$ (95% CI: 0.009–0.016) 1.64 (0.66); 1.28 (0.72); 1.14 (0.74); 1.14 (0.77); 1.14 (0.74); 1.16 (0.76); 1.14 (0.76); 1.14 (0.78); 1.16 (0.77); 1.15 (0.75); 1.24 (0.79)
Bjork et al. [69] (SE and US)	SE: 149 US: 85	SE: 56 (14) US: 53 (16)	SE: 68% US: 86%	SE: 2.4 (0.7) yrs US: 2.6 (4.3) yrs	5 yrs	SE: 0.6 (0.6) US: 0.8 (0.7)	Cross-sectional at two time-points and GEE	Mean (SD) score at baseline and 5 yrs. Adjusted slope	0.64–0.74 (SE) 0.74–0.85 (USA) SE: mean 0.68 (0.58) and USA: 0.80 (0.65) GEE coefficient –0.28 (95% CI: –0.44 to –0.13)
Shidara et al. [71] (JP)	1226	59 (52–67)	81.6%	10 (4–16) yrs	5 yrs	0.6 (0.1–1.3)	Multivariate linear regression Linear mixed model over 5 yrs	Adjusted slope at 1st, 3rd and 5th yr Adjusted slope	Anti-CCP+ vs Anti-CCP– : 1st yr ($\beta = 0.0335$); 2nd ($\beta = 0.0317$); 3rd yr ($\beta = 0.0199$) RF+ vs RF– : 1st yr ($\beta = 0.0004$); 2nd yr ($\beta = 0.0095$); 3rd yr ($\beta = 0.0108$) Anti-CCP+ : $\beta = 0.00657$ Anti-CCP– : $\beta = 0.00346$ RF+ : $\beta = 0.00613$ RF– : $\beta = 0.00617$

n = number of participants; data on age, disease duration or follow-up duration are mean (SD) or median (IQR); HAQ = health assessment questionnaire; M-HAQ = modified HAQ; yrs = years; L = alive at follow-up; D = died; LFU = lost to follow-up; NA = not available; W = women; M = men; MA = married; UNM = unmarried; RA = rheumatoid arthritis; C = control; CS = corticosteroids; NCS = not using corticosteroids; MTX = methotrexate; HCQ = hydroxychloroquine; RF = rheumatoid factor; anti-CCP = anti-cyclic citrullinated peptide antibody; DR4 = HLA-DR4 –/+ antigen negative and positive; MMP3 +/– = matrix metalloproteinase positive/negative; RF +/– = rheumatoid factor positive/negative; s = subset; T = treated; NT = untreated; Data on HAQ progression are mean (SD) = mean (stand deviation); β (95% CI) = β -coefficient (95% confidence interval); unadj = unadjusted; GEE = generalised estimating equations; OLS fixed effects = ordinary least square; AUC = area under curve.

^a Fee for service.

^b Managed care.

^c HAQ score was not converted to a 0–3 score.

subgroups. Two studies constructed percentile curve reference charts [51,57]. Lassere et al. [51] constructed percentile charts stratified by age, gender and disease duration. No overlap between the 10th, 50th and 90th percentile curves was observed when disease duration was included as a time-dependent variable. Wolfe [33] focused on the identification of distinct subgroups of patients with similar progression patterns. In this study, changes at the individual level were examined, observing that HAQ progression did in general not follow a linear trend and could not be readily categorised into distinct subgroups such as remitting, progressive and fluctuating.

In 2013, a novel approach to model individual HAQ progression combined with a form of cluster analysis to identify groups with similar trajectories was published by Norton et al. [24]. This study identified four common progression subgroups. Since this approach is novel and it is not clear whether the results are generalisable, the following section shows the findings in which this approach was repeated in the ERAS cohort, extending the follow-up period to 15 years, and in NOAR.

Results of HAQ trajectories ERAS and NOAR cohorts

A total of 1460 ERAS patients and 1027 NOAR patients were included in this study. The corresponding mean (SD) age was 55.2 (14.6) and 53.3 (15.9) years; and 67.1% and 64.8% were women (Table 2). Although symptom duration was almost similar between the two cohorts (~8 months), compared to the NOAR population, mean (SD) disease severity at baseline in the ERAS population was slightly higher, i.e., the DAS28 score was 4.00 (1.43) compared to 5.46 (1.74) and the HAQ score was 0.87 (0.73) compared to 1.15 (0.77), respectively. Furthermore, more patients in ERAS fulfilled the 1987 criteria for RA compared to patients in NOAR (70.6% vs 46.9%, respectively). These differences are probably a reflection of the different referral criteria used for both the cohorts.

HAQ trajectories

A total of 1352 patients in ERAS and 830 patients in NOAR with complete data on HAQ and covariates were included in the two separate models. Independently, in both cohorts, a four-subgroup LCGM was selected as providing the best fit and most parsimony. Although AIC or BIC preferred a larger number of subgroups, the likelihood ratio test was in favour of a four-subgroup model against a five (or more)-subgroup model. The subgroups identified were similar in terms of the shape of the trajectories and the distribution of patients between subgroups (Fig. 1). Three subgroups exhibited a J-shaped trajectory (subgroups: “low,” “moderate”

and “high”). A fourth subgroup (“severe”) experienced persistently high HAQ scores that increased early in the course of the disease and remained during the 15-year follow-up period. The percentage of patients allocated to each of the four subgroups was also very similar between the two cohorts, ERAS and NOAR, respectively: low (21.3% vs 21.2%); moderate (33.4% vs 31.9%); high (29.5% vs 26.5%); and severe (15.8% vs 20.3%). The percentage of patients using methotrexate at any time during follow-up increased with increasing subgroup of worse HAQ trajectory ranging from 27.8% in the low subgroup membership group to 48.3% in the severe subgroup in ERAS (Fig. 2). The percentage ranged from 8.9% to 38.2% in NOAR. In both the cohorts only 3.8% of patients received a biologics during follow-up. The percentage of patients receiving biologics was 5.3% in the severe subgroup of both cohorts, which was lower than in the high subgroup, 5.9% and 7.7% in ERAS and NOAR, respectively (Fig. 3).

Predictors of subgroup membership

In both ERAS and NOAR, older age, female gender and worse DAS28 score were significantly associated with increased likelihood of all subgroup memberships (low = reference, moderate, high and severe) of worse HAQ progression (Table 3). Although less consistent across the cohorts, there was also a statistically significant association or a trend towards a positive association between longer symptom duration, fulfilment of the 1987 ACR criteria of RA and lower SES with higher risk class membership. No association was found between RF and subgroup membership. Actual model coefficients are presented in Appendix.

Discussion

This article gives an overview of the methods used to evaluate HAQ changes over time in previous publications and shows the results of a comparison study in two observational cohorts, ERAS and NOAR, including patients with early IP and RA using a latent class growth model. Across previously published studies, between studies using the same database [eg, the USA National Data Bank for Rheumatic Diseases (NDB)] but applying different statistical methods, there was some variation in mean/median annual change between the studies (ranging from 0.01 to > 0.03), which might partly be explained by differences in disease duration at baseline, HAQ score at baseline, methods used to deal with missing data of patients who were lost to follow-up or died or the statistical methods used. Methods to assess change in HAQ scores over time varied from cross-sectional analysis, calculating raw change score and repeated measurement regression analysis. The advantages of the latter analysis are that they model the sources of variation and correlation that arise from, for example, observations taken from the same subject at multiple time-points, violating assumptions of within-subject independence. Most of these models are useful when assuming that in a given sample, individuals are expected to change in the same direction across time with only the degree of change varying between people. However, we know from individual patient data that both the strength and the direction of change are varying between patients. Wolfe [33] identified three patterns of individual courses: patients who had a high HAQ score at baseline and remained high, patients with fluctuating HAQ scores over time to be associated with variability in inflammation and pain over time and patients who started low and remained low. To address this problem, alternative modelling strategies such as LCGM are available considering multi-nominal heterogeneity in change. Another advantage of a LCGM is that it can be used for incomplete longitudinal data either due to lost to follow-up or due to intermittent missing data by assuming missing

Table 2
Demographic and clinical baseline characteristics of patients included in the ERAS cohort and patients included in the NOAR cohort

	% missing	ERAS n = 1460	% missing	NOAR n = 1027
Age at onset, years	0	55.2 (14.6)	0	53.3 (15.9)
Gender, % female	0	67.1%	0	64.8%
Symptom duration, months	0	8.2 (7.6)	0	8.6 (9.2)
HAQ score	0.3	1.15 (0.77)	0	0.87 (0.73)
DAS28 score	0.9	5.46 (1.74)	18.9	4.00 (1.43)
Rheumatoid factor, % positive	1.0	72.7%	11.7	28.3%
ACR 1987 criteria for RA, % yes	0	70.6%	0	46.9%
Socio-economic status, % most deprived	5.7	18.6%	0	12.5%
DMARDs	0	71.2%	0	16.4%

Values are mean (SD) for continuous variables or numbers (%) for categorical variables. DAS28 = 28 joint Disease Activity Score; HAQ = Health Assessment Questionnaire; DMARDs = Disease-Modifying Anti-Rheumatic Drugs.




Fig. 2. Censored normal 4-class LCGM observed (---) and expected trajectories (—) of functional disability in NOAR and ERAS.

at random. Also, a LCGM is a finite mixture model, where the mixture distribution offers a good fit for non-normal distributed outcomes such as HAQ. As far as we know, this is the first time that this model is used to independently identify similar common trajectories of HAQ progression in patients with IP and RA in two observational cohorts, ERAS and NOAR, following a large group of patients with early IP and RA for 15 years. In both the cohorts, four subgroups were identified showing very similar trajectories, i.e., patients who had a high HAQ score at baseline and did not improve (severe subgroup), patients who had a low HAQ score, improved and remained to have low HAQ scores over time (low subgroup) and two classes with a similar pattern, but distinct starting point (moderate and high subgroup). Age, gender, symptom duration, the ACR 1987 criteria for RA, DAS28 score RF and SES were included as indicators into the model. Of the demographic and clinical variables, all but RF were significant predictors for identifying patients in one or more membership subgroups.

The results presented in this article are a first step towards personalised medicine, and these initial findings may further help

to develop probability scores of patients belonging to one of the four groups. The information might also be useful in clinic to help target therapy. In this study, we noticed, for example, that compared to the high membership subgroup, the percentage of patients using methotrexate was similar and the percentage of patients using biologics was even lower in the severe subgroup, suggesting that the patients in the severe subgroup need to be treated more aggressively.

The identified predictors were very similar to those reported in the publications reviewed in this article that investigated possible predictors: older age [8,33,43,69], female gender [8,33,43,69], disease duration [33,43] and disease activity [8]. Gardiner et al. [19], however, did not find an association between age, gender or disease duration and change in HAQ score. Although concurrent illness was associated with change in HAQ score in the latter study, an observation seen in other studies as well [24,74,75], we were not able to include co-morbidity as one of the indicators in our models since co-morbidities were not reported consistently between the two cohorts. For that reason we also did not include radiographic joint damage, a predictor seen in some of the reviewed studies. However, since both ERAS and NOAR include patients with early IP or RA, the contribution of baseline radiographic damage to identify subgroups would probably have been minimal. Overall, identification of the four subgroups and their indicators is of importance when assessing patients with early RA in clinic, and the information could be used to tailor treatment to the individual patient.

There were also some limitations to this study. In the comparison study, the referral criteria differed between the two cohorts, resulting in patients recruited to ERAS having slightly higher disease activity and more often being classified as having RA at baseline compared to patients in NOAR. This discrepancy, however, did not result in different models or identification of different predictors. Both IP and RA patients were included in both cohorts, but this is probably also a reflection of a general arthritis population seen in clinic.

The authors conclude that a diverse range of methods exists for assessing the progression of disability in RA. As a consequence, there is no appropriate way to combine previous published research in the field. However, the ERAS and NOAR cohorts showed that HAQ progression could be placed into four HAQ trajectory subgroups. These subgroups were nearly identical between these cohorts, which supports their validity. Identifying distinct groups of patients who are at risk of poor functional outcome is likely to help target therapy to those who are most likely to benefit.




Fig. 3. Percentage of patients receiving methotrexate (A) or biologics (B) during follow-up in each of the four class membership groups. ■—ERAS cohort and ■—NOAR cohort.

Table 3
Predictors of class membership in ERAS and NOAR

Class membership	ERAS				NOAR			
	Odds ratio	z	p	95% CI	Odds ratio	z	p	95% CI
Age at onset								
Low	1.00				1.00			
Moderate	1.03	3.73	0.00	1.01–1.04	1.03	3.54	0.000	1.01–1.05
High	1.04	5.44	0.00	1.02–1.05	1.05	5.08	0.000	1.03–1.06
Severe	1.09	7.76	0.00	1.06–1.11	1.08	7.24	0.000	1.06–1.10
Female gender								
Low	1.00				1.00			
Moderate	2.32	4.30	0.000	1.58–3.40	2.38	3.42	0.001	1.45–3.92
High	5.44	7.93	0.000	3.58–8.28	2.76	3.76	0.000	1.63–4.68
Severe	7.21	7.34	0.000	4.26–12.22	8.21	6.32	0.000	4.28–15.76
Symptom duration, months								
Low	1.00				1.00			
Moderate	1.03	1.99	0.046	1.00–1.07	1.01	0.59	0.553	0.98–1.04
High	1.05	2.78	0.005	1.01–1.08	1.03	1.86	0.063	1.00–1.05
Severe	1.04	2.01	0.044	1.00–1.09	1.05	3.21	0.001	1.02–1.08
DAS28 score								
Low	1.00				1.00			
Moderate	1.36	3.81	0.000	1.16–1.59	1.48	3.42	0.001	1.18–1.85
High	1.77	7.50	0.000	1.53–2.06	1.87	5.34	0.000	1.48–2.35
Severe	2.23	9.26	0.000	1.88–2.63	3.17	8.50	0.000	2.43–4.13
Rheumatoid factor positive								
Low	1.00				1.00			
Moderate	1.24	0.90	0.368	0.78–1.97	1.47	1.19	0.233	0.78–2.78
High	1.37	1.26	0.207	0.84–2.24	1.58	1.44	0.151	0.84–2.97
Severe	1.35	1.03	0.304	0.76–2.38	2.36	2.42	0.016	1.18–4.73
The 1987 criteria for RA								
Low	1.00				1.00			
Moderate	1.32	1.24	0.216	0.85–2.05	1.23	0.64	0.524	0.66–2.29
High	1.51	1.75	0.081	0.95–2.40	2.20	2.53	0.011	1.19–4.06
Severe	2.56	2.97	0.003	1.38–4.75	2.04	2.01	0.044	1.02–4.10
Socio-economic status								
Low	1.00				1.00			
Moderate	2.70	2.71	0.007	1.32–5.53	1.42	0.78	0.433	0.59–3.38
High	3.06	3.27	0.001	1.56–5.98	3.07	2.72	0.007	1.37–6.91
Severe	4.17	3.75	0.000	1.98–8.81	3.43	2.61	0.009	1.36–8.66

DAS28 = 28 joint Disease Activity Score; p = p-value for statistical significance; 95% CI = 95% confidence interval odds ratio.

Acknowledgements

We thank the rheumatologists, research nurses and data management teams working for ERAS and NOAR for their major contribution to data collection and data management.

Appendix. Supplementary Information

Supplementary data associated with this article can be found in the online version at <http://dx.doi.org/10.1016/j.semarthrit.2014.05.003>.

References

- [1] Lillegraven S, Kvien TK. Measuring disability and quality of life in established rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2007;21:827–40.
- [2] Smolen JS, Aletaha D. Patients with rheumatoid arthritis in clinical care. *Ann Rheum Dis* 2004;63:221–5.
- [3] Farragher TM, Lunt M, Bunn DK, Silman AJ, Symmons DP. Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. *Ann Rheum Dis* 2007;66:486–92.
- [4] Sokka T, Hakkinen A, Krishnan E, Hannonen P. Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. *Ann Rheum Dis* 2004;63:494–7.
- [5] Bombardier C, Barbieri M, Parthan A, Zack DJ, Walker V, Macarios D, et al. The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review. *Ann Rheum Dis* 2012;71:836–44.
- [6] Verstappen SM, Bijlsma JW, Verkleij H, Buskens E, Blaauw AA, ter Borg EJ, et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. *Arthritis Rheum* 2004;51:488–97.
- [7] Young A, Dixey J, Kulinskaya E, Cox N, Davies P, Devlin J, et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). *Ann Rheum Dis* 2002;61:335–40.
- [8] Welsing PM, van Gestel AM, Swinkels HL, Kiemeny LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. *Arthritis Rheum* 2001;44:2009–17.
- [9] Hazes JM. Determinants of physical function in rheumatoid arthritis: association with the disease process. *Rheumatology (Oxford)* 2003;42(Suppl. 2):ii17–ii21.
- [10] Drossaers-Bakker KW, de BM, van ZD, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. *Arthritis Rheum* 1999;42:1854–60.
- [11] Bansback N, Young A, Brennan A, Dixey J. A prognostic model for functional outcome in early rheumatoid arthritis. *J Rheumatol* 2006;33:1503–10.
- [12] Young A, Dixey J, Cox N, Davies P, Devlin J, Emery P, et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). *Rheumatology (Oxford)* 2000;39:603–11.
- [13] Combe B, Cantagrel A, Goupille P, Bozonnet MC, Sibilia J, Eliaou JF, et al. Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis. *J Rheumatol* 2003;30:2344–9.
- [14] Wiles N, Dunn G, Barrett E, Silman A, Symmons D. Associations between demographic and disease-related variables and disability over the first five

- years of inflammatory polyarthritis: a longitudinal analysis using generalized estimating equations. *J Clin Epidemiol* 2000;53:988–96.
- [15] Guillemin F, Suurmeijer T, Krol B, Bombardier C, Briancon S, Doeglas D, et al. Functional disability in early rheumatoid arthritis: description and risk factors. *J Rheumatol* 1994;21:1051–5.
 - [16] Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. *Rheumatology (Oxford)* 2006;45:478–80.
 - [17] Bansback N, Marra CA, Finckh A, Anis A. The economics of treatment in early rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2009;23:83–92.
 - [18] Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, et al. The links between joint damage and disability in rheumatoid arthritis. *Rheumatology (Oxford)* 2000;39:122–32.
 - [19] Gardiner PV, Sykes HR, Hassey GA, Walker DJ. An evaluation of the Health Assessment Questionnaire in long-term longitudinal follow-up of disability in rheumatoid arthritis. *Br J Rheumatol* 1993;32:724–8.
 - [20] Michaud K, Wallenstein G, Wolfe F. Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patients. *Arthritis Care Res (Hoboken)* 2011;63:366–72.
 - [21] Harrison MJ, Farragher TM, Clarke AM, Manning SC, Bunn DK, Symmons DP. Association of functional outcome with both personal- and area-level socioeconomic inequalities in patients with inflammatory polyarthritis. *Arthritis Rheum* 2009;61:1297–304.
 - [22] Marra CA, Lynd LD, Esdaile JM, Kopec J, Anis AH. The impact of low family income on self-reported health outcomes in patients with rheumatoid arthritis within a publicly funded health-care environment. *Rheumatology (Oxford)* 2004;43:1390–7.
 - [23] Scott DL, Smith C, Kingsley G. Joint damage and disability in rheumatoid arthritis: an updated systematic review. *Clin Exp Rheumatol* 2003;21:S20–7.
 - [24] Norton S, Sacker A, Dixey J, Done J, Williams P, Young A, et al. Trajectories of functional limitation in early rheumatoid arthritis and their association with mortality. *Rheumatology (Oxford)* 2013;52:2016–24.
 - [25] Young A. Short-term outcomes in recent-onset rheumatoid arthritis. *Br J Rheumatol* 1995;34(Suppl. 2):79–86.
 - [26] Symmons DP, Barrett EM, Bankhead CR, Scott DG, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. *Br J Rheumatol* 1994;33:735–9.
 - [27] Wiles NJ, Dunn G, Barrett EM, Harrison BJ, Silman AJ, Symmons DP. One year followup variables predict disability 5 years after presentation with inflammatory polyarthritis with greater accuracy than at baseline. *J Rheumatol* 2000;27:2360–6.
 - [28] Kirwan JR, Reebeck JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. *Br J Rheumatol* 1986;25:206–9.
 - [29] Nagin DS, Tremblay RE. Analyzing developmental trajectories of distinct but related behaviors: a group-based method. *Psychol Methods* 2001;6:18–34.
 - [30] van Zeben D, Hazes JM, Zwinderman AH, Cats A, Schreuder GM, D'Amaro J, et al. Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study. *Arthritis Rheum* 1991;34:822–30.
 - [31] Wolfe F, Hawley DJ, Cathey MA. Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis. *J Rheumatol* 1991;18:1290–7.
 - [32] Munro R, Hampson R, McEntegart A, Thomson EA, Madhok R, Capell H. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. *Ann Rheum Dis* 1998;57:88–93.
 - [33] Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. *Arthritis Rheum* 2000;43:2751–61.
 - [34] Kroot EJ, van Leeuwen MA, van Rijswijk MH, Prevoo ML, van 't Hof MA, van de Putte LB, et al. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. *Ann Rheum Dis* 2000;59:954–8.
 - [35] Ahlmen M, Svensson B, Albertsson K, Forslind K, Hafstrom I. Influence of gender on assessments of disease activity and function in early rheumatoid arthritis in relation to radiographic joint damage. *Ann Rheum Dis* 2010;69:230–3.
 - [36] Benton N, Stewart N, Crabbe J, Robinson E, Yeoman S, McQueen FM. MRI of the wrist in early rheumatoid arthritis can be used to predict functional outcome at 6 years. *Ann Rheum Dis* 2004;63:555–61.
 - [37] Persson LO, Larsson BM, Nived K, Eberhardt K. The development of emotional distress in 158 patients with recently diagnosed rheumatoid arthritis: a prospective 5-year follow-up study. *Scand J Rheumatol* 2005;34:191–7.
 - [38] Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, et al. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. *Semin Arthritis Rheum* 2007;37:99–111.
 - [39] Courvoisier N, Dougados M, Cantagrel A, Goupille P, Meyer O, Sibilia J, et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. *Arthritis Res Ther* 2008;10:R106.
 - [40] Farragher TM, Lunt M, Fu B, Bunn D, Symmons DP. Early treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis. *Ann Rheum Dis* 2010;69:689–95.
 - [41] Benka J, Nagyova I, Rosenberger J, Calfova A, Macejova Z, Middel B, et al. Social support and psychological distress in rheumatoid arthritis: a 4-year prospective study. *Disabil Rehabil* 2012;34:754–61.
 - [42] Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. *J Rheumatol* 1982;9:789–93.
 - [43] Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF. The development of disability in rheumatoid arthritis. *Arthritis Rheum* 1986;29:494–500.
 - [44] Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. *J Rheumatol* 1991;18:1298–306.
 - [45] Epstein WV, Henke CJ, Yelin EH, Katz PP. Effect of parenterally administered gold therapy on the course of adult rheumatoid arthritis. *Ann Intern Med* 1991;114:437–44.
 - [46] Hawley DJ, Wolfe F. Sensitivity to change of the health assessment questionnaire (HAQ) and other clinical and health status measures in rheumatoid arthritis: results of short-term clinical trials and observational studies versus long-term observational studies. *Arthritis Care Res* 1992;5:130–6.
 - [47] Leigh JP, Fries JF, Parikh N. Severity of disability and duration of disease in rheumatoid arthritis. *J Rheumatol* 1992;19:1906–11.
 - [48] Guillemin F, Briancon S, Pourel J. Functional disability in rheumatoid arthritis: two different models in early and established disease. *J Rheumatol* 1992;19:366–9.
 - [49] Ward MM, Leigh JP. Marital status and the progression of functional disability in patients with rheumatoid arthritis. *Arthritis Rheum* 1993;36:581–8.
 - [50] Leigh JP, Fries JF. Tobit, fixed effects, and cohort analyses of the relationship between severity and duration of rheumatoid arthritis. *Soc Sci Med* 1993;36:1495–502.
 - [51] Lasserre M, Wells G, Tugwell P, Edmonds J. Percentile curve reference charts of physical function: rheumatoid arthritis population. *J Rheumatol* 1995;22:1241–6.
 - [52] Ward MM, Lubeck D, Leigh JP. Longterm health outcomes of patients with rheumatoid arthritis treated in managed care and fee-for-service practice settings. *J Rheumatol* 1998;25:641–9.
 - [53] Clarke AE, St-Pierre Y, Joseph L, Penrod J, Sibley JT, Haga M, et al. Radiographic damage in rheumatoid arthritis correlates with functional disability but not direct medical costs. *J Rheumatol* 2001;28:2416–24.
 - [54] Gordon P, West J, Jones H, Gibson T. A 10 year prospective followup of patients with rheumatoid arthritis 1986–96. *J Rheumatol* 2001;28:2409–15.
 - [55] Hurst S, Kallan MJ, Wolfe FJ, Fries JF, Albert DA. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects. *J Rheumatol* 2002;29:1639–45.
 - [56] Krishnan E, Fries JF. Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients. *Am J Med* 2003;115:371–6.
 - [57] Krishnan E, Tugwell P, Fries JF. Percentile benchmarks in patients with rheumatoid arthritis: Health Assessment Questionnaire as a quality indicator (QI). *Arthritis Res Ther* 2004;6:R505–13.
 - [58] Demange V, Guillemin F, Baumann A, Suurmeijer TP, Moum T, Doeglas D, et al. Are there more than cross-sectional relationships of social support and support networks with functional limitations and psychological distress in early rheumatoid arthritis? the European Research on Incapacitating Diseases and Social Support Longitudinal Study. *Arthritis Rheum* 2004;51:782–91.
 - [59] Baddoura R, Haddad S, Awada H, Al-Masri AF, Merheb G, Attoui S, et al. Severity of rheumatoid arthritis: the SEVERA study. *Clin Rheumatol* 2006;25:700–4.
 - [60] Sokka T, Kautiainen H, Hannonen P, Pincus T. Changes in Health Assessment Questionnaire disability scores over five years in patients with rheumatoid arthritis compared with the general population. *Arthritis Rheum* 2006;54:3113–8.
 - [61] Shinozaki M, Inoue E, Nakajima A, Hara M, Tomatsu T, Kamatani N, et al. Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. *Mod Rheumatol* 2007;17:403–8.
 - [62] Odegard S, Finset A, Mowinckel P, Kvien TK, Uhlig T. Pain and psychological health status over a 10-year period in patients with recent onset rheumatoid arthritis. *Ann Rheum Dis* 2007;66:1195–201.
 - [63] Gonzalez-Alvaro I, Descalzo MA, Carmona L. Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohort. *Arthritis Res Ther* 2008;10:R138.
 - [64] Ranganath VK, Paulus HE, Onofrei A, Khanna D, Reed G, Elashoff DA, et al. Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database. *J Rheumatol* 2008;35:1966–71.
 - [65] Iikuni N, Sato E, Hoshi M, Inoue E, Taniguchi A, Hara M, et al. The influence of sex on patients with rheumatoid arthritis in a large observational cohort. *J Rheumatol* 2009;36:508–11.
 - [66] Bazzani C, Filippini M, Caporali R, Bobbio-Pallavicini F, Favalli EG, Marchesoni A, et al. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. *Autoimmun Rev* 2009;8:260–5.
 - [67] Wolfe F, Michaud K. The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. *Arthritis Res Ther* 2010;12:R35.

- [68] Staples MP, March L, Lassere M, Reid C, Buchbinder R. Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database. *Rheumatology (Oxford)* 2011;50:166–75.
- [69] Bjork M, Trupin L, Thyberg I, Katz P, Yelin E. Differences in activity limitation, pain intensity, and global health in patients with rheumatoid arthritis in Sweden and the USA: a 5-year follow-up. *Scand J Rheumatol* 2011;40:428–32.
- [70] Iikuni N, Inoue E, Tanaka E, Hara M, Tomatsu T, Kamatani N, et al. Low disease activity state with corticosteroid may not represent “true” low disease activity state in patients with rheumatoid arthritis. *Rheumatology (Oxford)* 2008;47:519–21.
- [71] Shidara K, Inoue E, Hoshi D, Sato E, Nakajima A, Momohara S, et al. Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. *Rheumatol Int* 2012;32:361–6.
- [72] Wolfe F, Cathey MA. The effect of age on methotrexate efficacy and toxicity. *J Rheumatol* 1991;18:973–7.
- [73] Leigh JP, Fries JF. Predictors of disability in a longitudinal sample of patients with rheumatoid arthritis. *Ann Rheum Dis* 1992;51:581–7.
- [74] Radner H, Smolen JS, Aletaha D. Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. *Rheumatology (Oxford)* 2011;50:381–8.
- [75] Cho SK, Sung YK, Choi CB, Cha HS, Choe JY, Chung WT, et al. Do patients with elderly-onset rheumatoid arthritis have severe functional disability? *Semin Arthritis Rheum* 2012;42:23–31.